<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01662180</url>
  </required_header>
  <id_info>
    <org_study_id>PRORAILS trial</org_study_id>
    <nct_id>NCT01662180</nct_id>
  </id_info>
  <brief_title>Predicting Ovarian Response in Artificial Insemination With Low Stimulation</brief_title>
  <official_title>Predicting Ovarian Response in Artificial Insemination With Low Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Isala</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This large prospective multi-center cohort study aims to identify patient's characteristics&#xD;
      that significantly influence ovarian response to mild stimulation with a fixed dose of 75 IU&#xD;
      recombinant FSH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, open-label, prospective cohorts study. Patients with a regular indication for&#xD;
      COH/IUI (controlled ovarian stimulation/ intra uterine insemination) will be asked to&#xD;
      participate. Patient's characteristics will be documented including age, weight, BMI, smoking&#xD;
      status, cycle day 2 3 or 4 FSH /Estradiol levels, antral follicle count, and AMH. AMH and&#xD;
      FSH/Estradiol will be determined centrally after completion of inclusion of all patients in&#xD;
      the study. All patients will receive a fixed 75 IU recFSH per day conform normal stimulation&#xD;
      protocol starting from cycle day 3, 4 or 5 after exclusion of ovarian cysts by ultrasound.&#xD;
      Ovarian response will be documented by ultrasound only. Once the dominant follicle(s) reach a&#xD;
      mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be&#xD;
      scheduled 36-42 hours later. Cancellation criteria will be defined according to the national&#xD;
      guidelines provided by the NVOG (7).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the relationship between AMH serum levels and ovarian response</measure>
    <time_frame>one menstrual cycle, one month</time_frame>
    <description>(defined by the number of dominant follicles &gt;15mm) in IUI cycles stimulated with a fixed dose of 75 IU recFSH. All follicles &gt; 11 mm will be documented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the relationship between age, weight, BMI, smoking, AFC, FSH/E2 on CD3 and ovarian response</measure>
    <time_frame>one menstrual cycle, one month</time_frame>
    <description>(defined by the number of dominant follicles &gt;15mm) in IUI cycles stimulated with a fixed dose of 75 IU recFSH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate per started cycle.</measure>
    <time_frame>three months</time_frame>
    <description>From start of the menstrual cycle until a positive heartbeat registered at 12 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate per started cycle.</measure>
    <time_frame>three months</time_frame>
    <description>From start of the menstrual cycle until positive heartbeats registered at 12 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate per started cycle.</measure>
    <time_frame>five months</time_frame>
    <description>miscarriage up to 16 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation rate per stimulated cycle</measure>
    <time_frame>one menstrual cycle, one month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Subfertile couples</arm_group_label>
    <description>Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles&#xD;
All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follicle Stimulating Hormone</intervention_name>
    <description>All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.</description>
    <arm_group_label>Subfertile couples</arm_group_label>
    <other_name>Puregon [Merck Sharp &amp; Dohme bv]</other_name>
    <other_name>Gonal -F [Serono Benelux bv]</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample tested for FSH, E2 and AMH&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated&#xD;
        cycles&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  couples with unexplained or mild male subfertility (1-3) and a spontaneous chance of&#xD;
             conception below 40% (Hunault score).&#xD;
&#xD;
          -  Unexplained subfertility including minimal to mild endometriosis (AFS grade 1 or 2) is&#xD;
             defined as the failure to conceive after at least one year of unprotected intercourse&#xD;
             whereas the standard fertility work-up was unable to detect any factors that might&#xD;
             influence fertility negatively.&#xD;
&#xD;
          -  semen analysis should be normal according to the WHO guidelines (8),&#xD;
&#xD;
          -  ovulation should be documented (by BBT charts, ovulation detection by ultrasound or&#xD;
             normal luteal progesterone values),&#xD;
&#xD;
          -  tubal patency should be confirmed (HSG, laparoscopy or fertiloscopy) and when a&#xD;
             postcoital test was performed a cervical factor should have been excluded.&#xD;
&#xD;
          -  Mild male subfertility is defined as abnormal semen parameters according to the WHO&#xD;
             (8) but an average total motile sperm account before processing of at least 10&#xD;
             million.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hunault score ≥ 40%&#xD;
&#xD;
          -  Endometriosis AFS grade 3 or 4&#xD;
&#xD;
          -  Contra-indications for the use of gonadotrophins (cysts larger than 2 cm, allergy for&#xD;
             gonadotrophins)&#xD;
&#xD;
          -  Total motile sperm count after sperm processing below 1 million&#xD;
&#xD;
          -  Women aged younger than eighteen years or older than 45 years.&#xD;
&#xD;
          -  Previous treatment with COH/IUI for treating current subfertility&#xD;
&#xD;
          -  Unable to speak or read the Dutch language&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Cohlen, dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maaike M Bloemendal, Drs.</last_name>
    <phone>0031384247506</phone>
    <email>m.m.bloemendal@isala.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ben Cohlen, Dr.</last_name>
    <phone>0031384247570</phone>
    <email>b.cohlen@isala.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <state>Po 95500</state>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugenie Kaaijk, dr.</last_name>
      <phone>0031205993481</phone>
      <email>e.m.kaaijk@olvg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Logtenberg</last_name>
      <phone>003120-5999111</phone>
      <email>s.l.m.logtenberg@olvg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Eugenie Kaaijk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>PO Box 10400</state>
        <zip>8000 GK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maaike Bloemendal, Drs.</last_name>
      <phone>0031384247506</phone>
      <email>m.m.bloemendal@isala.nl</email>
    </contact>
    <contact_backup>
      <last_name>Henriette Hulsebos</last_name>
      <phone>0031384247783</phone>
      <email>h.j.m.hulsebos@isala.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Ben Cohlen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>PO box 1350</state>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minouche van Rumste, dr.</last_name>
      <phone>003140 239 71 00</phone>
      <email>minouche.v.rumste@catharinaziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Milou Peters</last_name>
      <phone>00316-5102 8887</phone>
      <email>milou.peters@catharinaziekenhuis.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Minouche van Rumste, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>PO box 22660</state>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fulco van der Veen, prof. dr.</last_name>
      <phone>003120 - 566 4287</phone>
      <email>f.vanderveen@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Tessa de Vries</last_name>
      <phone>00316 - 23799274</phone>
      <email>t.s.devries@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Fulco van der Veen, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <state>PO box 7057</state>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cornelis Lambalk, prof. dr.</last_name>
      <phone>0031204444444</phone>
      <email>cb.lambalk@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Angelique de Vos-Brouwer</last_name>
      <phone>003120-4442180</phone>
      <email>m.devos-brouwer@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Cornelis Lambalk, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <state>PO box 85500</state>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Broekmans, prof. dr.</last_name>
      <phone>088-7551041</phone>
      <email>f.broekmans@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marian Kosterman</last_name>
      <phone>088-7555555</phone>
      <email>M.J.T.Kosterman@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Broekmans, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>st Elizabeth Gasthuis</name>
      <address>
        <city>Tilburg</city>
        <state>PO box 90151</state>
        <zip>5000 LC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper Smeenk, dr.</last_name>
      <phone>0031013539 30 06</phone>
      <email>j.smeenk@elizabeth.nl</email>
    </contact>
    <investigator>
      <last_name>Jesper Smeenk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Bensdorp AJ, Cohlen BJ, Heineman MJ, Vandekerckhove P. Intra-uterine insemination for male subfertility. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000360. doi: 10.1002/14651858.CD000360.pub4.</citation>
    <PMID>17943739</PMID>
  </reference>
  <reference>
    <citation>Verhulst SM, Cohlen BJ, Hughes E, Te Velde E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001838. doi: 10.1002/14651858.CD001838.pub3.</citation>
    <PMID>17054143</PMID>
  </reference>
  <reference>
    <citation>Tummon IS, Asher LJ, Martin JS, Tulandi T. Randomized controlled trial of superovulation and insemination for infertility associated with minimal or mild endometriosis. Fertil Steril. 1997 Jul;68(1):8-12. doi: 10.1016/s0015-0282(97)81467-7.</citation>
    <PMID>9207576</PMID>
  </reference>
  <reference>
    <citation>Freiesleben NL, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Loft A, Bangsboll S, Pinborg A, Budtz-Jorgensen E, Andersen AN. Predictors of ovarian response in intrauterine insemination patients and development of a dosage nomogram. Reprod Biomed Online. 2008 Nov;17(5):632-41. doi: 10.1016/s1472-6483(10)60310-0.</citation>
    <PMID>18983747</PMID>
  </reference>
  <reference>
    <citation>la Cour Freiesleben N, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Rosendahl M, Loft A, Bangsboll S, Pinborg A, Nyboe Andersen A. Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study. Hum Reprod. 2009 Oct;24(10):2523-30. doi: 10.1093/humrep/dep239. Epub 2009 Jul 14.</citation>
    <PMID>19602518</PMID>
  </reference>
  <reference>
    <citation>Freiesleben Nl, Rosendahl M, Johannsen TH, Lossl K, Loft A, Bangsboll S, Friis-Hansen L, Pinborg A, Andersen AN. Prospective investigation of serum anti-Mullerian hormone concentration in ovulatory intrauterine insemination patients: a preliminary study. Reprod Biomed Online. 2010 May;20(5):582-7. doi: 10.1016/j.rbmo.2010.02.007. Epub 2010 Feb 12.</citation>
    <PMID>20303323</PMID>
  </reference>
  <reference>
    <citation>Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT, Vogelsong KM. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010 May-Jun;16(3):231-45. doi: 10.1093/humupd/dmp048. Epub 2009 Nov 24.</citation>
    <PMID>19934213</PMID>
  </reference>
  <reference>
    <citation>La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010 Mar-Apr;16(2):113-30. doi: 10.1093/humupd/dmp036. Epub 2009 Sep 30.</citation>
    <PMID>19793843</PMID>
  </reference>
  <reference>
    <citation>Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Mullerian hormone: clairvoyance or crystal clear? Hum Reprod. 2012 Mar;27(3):631-6. doi: 10.1093/humrep/der446. Epub 2012 Jan 11.</citation>
    <PMID>22238112</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>July 26, 2012</study_first_submitted>
  <study_first_submitted_qc>August 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2012</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isala</investigator_affiliation>
    <investigator_full_name>M. Bloemendal</investigator_full_name>
    <investigator_title>drs.</investigator_title>
  </responsible_party>
  <keyword>subfertility, IUI, rec FSH, FSH, E2, AMH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01662180
org study id: PRORAILS trial
nct id: NCT01662180
lead sponsor: 
collaborator: 
has dmc: No
This large prospective multi-center cohort study aims to identify patient's characteristics
      that significantly influence ovarian response to mild stimulation with a fixed dose of 75 IU
      recombinant FSH.
A multi-center, open-label, prospective cohorts study. Patients with a regular indication for
      COH/IUI (controlled ovarian stimulation/ intra uterine insemination) will be asked to
      participate. Patient's characteristics will be documented including age, weight, BMI, smoking
      status, cycle day 2 3 or 4 FSH /Estradiol levels, antral follicle count, and AMH. AMH and
      FSH/Estradiol will be determined centrally after completion of inclusion of all patients in
      the study. All patients will receive a fixed 75 IU recFSH per day conform normal stimulation
      protocol starting from cycle day 3, 4 or 5 after exclusion of ovarian cysts by ultrasound.
      Ovarian response will be documented by ultrasound only. Once the dominant follicle(s) reach a
      mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be
      scheduled 36-42 hours later. Cancellation criteria will be defined according to the national
      guidelines provided by the NVOG (7).
observational model: Cohort
time perspective: Prospective
measure: To assess the relationship between AMH serum levels and ovarian response
time frame: one menstrual cycle, one month
description: (defined by the number of dominant follicles >15mm) in IUI cycles stimulated with a fixed dose of 75 IU recFSH. All follicles > 11 mm will be documented
measure: To assess the relationship between age, weight, BMI, smoking, AFC, FSH/E2 on CD3 and ovarian response
time frame: one menstrual cycle, one month
description: (defined by the number of dominant follicles >15mm) in IUI cycles stimulated with a fixed dose of 75 IU recFSH.
measure: Pregnancy rate per started cycle.
time frame: three months
description: From start of the menstrual cycle until a positive heartbeat registered at 12 weeks of gestation.
measure: Multiple pregnancy rate per started cycle.
time frame: three months
description: From start of the menstrual cycle until positive heartbeats registered at 12 weeks of gestation.
measure: Miscarriage rate per started cycle.
time frame: five months
description: miscarriage up to 16 weeks of gestation
measure: Cancellation rate per stimulated cycle
time frame: one menstrual cycle, one month
arm group label: Subfertile couples
description: Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles
All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle.
intervention type: Drug
intervention name: Follicle Stimulating Hormone
description: All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
arm group label: Subfertile couples
other name: Puregon [Merck Sharp & Dohme bv]
other name: Gonal -F [Serono Benelux bv]
blood sample tested for FSH, E2 and AMH
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: 45 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Ben Cohlen, dr.
role: Principal Investigator
affiliation: Isala
last name: Maaike M Bloemendal, Drs.
phone: 0031384247506
email: m.m.bloemendal@isala.nl
last name: Ben Cohlen, Dr.
phone: 0031384247570
email: b.cohlen@isala.nl
facility: 
status: Not yet recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
country: Netherlands
citation: Bensdorp AJ, Cohlen BJ, Heineman MJ, Vandekerckhove P. Intra-uterine insemination for male subfertility. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000360. doi: 10.1002/14651858.CD000360.pub4.
PMID: 17943739
citation: Verhulst SM, Cohlen BJ, Hughes E, Te Velde E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001838. doi: 10.1002/14651858.CD001838.pub3.
PMID: 17054143
citation: Tummon IS, Asher LJ, Martin JS, Tulandi T. Randomized controlled trial of superovulation and insemination for infertility associated with minimal or mild endometriosis. Fertil Steril. 1997 Jul;68(1):8-12. doi: 10.1016/s0015-0282(97)81467-7.
PMID: 9207576
citation: Freiesleben NL, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Loft A, Bangsboll S, Pinborg A, Budtz-Jorgensen E, Andersen AN. Predictors of ovarian response in intrauterine insemination patients and development of a dosage nomogram. Reprod Biomed Online. 2008 Nov;17(5):632-41. doi: 10.1016/s1472-6483(10)60310-0.
PMID: 18983747
citation: la Cour Freiesleben N, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Rosendahl M, Loft A, Bangsboll S, Pinborg A, Nyboe Andersen A. Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study. Hum Reprod. 2009 Oct;24(10):2523-30. doi: 10.1093/humrep/dep239. Epub 2009 Jul 14.
PMID: 19602518
citation: Freiesleben Nl, Rosendahl M, Johannsen TH, Lossl K, Loft A, Bangsboll S, Friis-Hansen L, Pinborg A, Andersen AN. Prospective investigation of serum anti-Mullerian hormone concentration in ovulatory intrauterine insemination patients: a preliminary study. Reprod Biomed Online. 2010 May;20(5):582-7. doi: 10.1016/j.rbmo.2010.02.007. Epub 2010 Feb 12.
PMID: 20303323
citation: Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT, Vogelsong KM. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010 May-Jun;16(3):231-45. doi: 10.1093/humupd/dmp048. Epub 2009 Nov 24.
PMID: 19934213
citation: La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010 Mar-Apr;16(2):113-30. doi: 10.1093/humupd/dmp036. Epub 2009 Sep 30.
PMID: 19793843
citation: Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Mullerian hormone: clairvoyance or crystal clear? Hum Reprod. 2012 Mar;27(3):631-6. doi: 10.1093/humrep/der446. Epub 2012 Jan 11.
PMID: 22238112
responsible party type: Principal Investigator
investigator affiliation: Isala
investigator full name: M. Bloemendal
investigator title: drs.
mesh term: Infertility
mesh term: Hormones
mesh term: Follicle Stimulating Hormone